GLP-1's Surprising Second Job: Slowing Aging

Key takeaways

• In a study on older mice, semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan and improved multiple biological markers of aging, even when treatment started later in life.
• Treated mice showed better memory, muscle function, and blood sugar regulation than untreated mice, and median lifespan extended by nearly 100 days in mice treated until the end of life.
• When researchers compared semaglutide directly to calorie restriction, matched so both groups were eating the same reduced amount, the drug outperformed calorie restriction in several areas, suggesting it may work through a separate biological pathway rather than simply reflecting reduced food intake.
• The bigger picture: this raises a genuinely new question about whether this class of drug taps into the biology of aging itself, though this is mouse research, and whether the same effects appear in people remains unknown.

A familiar drug in an unfamiliar spotlight

Semaglutide has become widely known for its effects on appetite and blood sugar, but researchers at UC Berkeley, supported by the National Institutes of Health, wanted to know whether the drug's reach might extend further, into the biological processes underlying aging itself. Earlier animal research had already hinted that GLP-1 drugs could delay the onset of a wide variety of age-related health conditions, which raised the question of whether something more fundamental was happening beneath the surface.

To find out, the team turned to older mice and a rigorous side-by-side comparison.

What happened when older mice got the drug

Researchers gave semaglutide to 20-month-old female mice, roughly equivalent to late middle age in mouse terms, for three months. Compared with untreated mice, the treated animals showed better muscle and cognitive performance, along with gene activity changes pointing to reduced inflammation and an improved capacity for tissue repair and regeneration.

In a separate group of mice treated with semaglutide for the rest of their lives, the results were striking: median lifespan extended by nearly 100 days compared with untreated animals, a meaningful gain in mouse-lifespan terms.

Ruling out the simplest explanation

Because semaglutide reduces appetite, researchers needed to rule out the possibility that these benefits were simply a byproduct of eating less. To test this, they compared semaglutide directly against calorie restriction, one of the most well-established interventions for extending lifespan in lab animals, carefully matching the calorie-restricted group's food intake to what the semaglutide-treated mice were naturally eating.

Many effects overlapped between the two approaches. But semaglutide pulled ahead in specific areas: treated mice improved beyond their own starting levels in exploratory behavior, spatial memory, and blood sugar regulation, and their metabolic rate stayed steady, while it slowed down in the calorie-restricted group. That divergence suggests semaglutide isn't just mimicking the effects of eating less, it may be engaging a distinct biological pathway tied to aging.

A longevity lens: is this more than an appetite drug

This finding fits into a broader and increasingly interesting conversation in aging research: many chronic health conditions appear to share the aging process itself as a common root, so an intervention that meaningfully slows aging could plausibly explain benefits across a surprisingly wide range of outcomes. That's a different framing than simply thinking of these drugs as an appetite or blood sugar tool, it repositions them as a potential entry point into aging biology more broadly.

Researchers were careful to note that this doesn't mean semaglutide extends human lifespan. The mouse data is compelling, but translating findings like this into people, especially people without existing weight or blood sugar concerns, will require dedicated clinical research that hasn't been done yet.

The takeaway

This is an early, animal-based finding, not a green light to think about GLP-1 drugs as longevity treatments. But it's a genuinely interesting scientific development: a drug already used by millions may be doing something to the aging process itself, separate from its known effects on appetite and metabolism. Whether that translates to people is one of the more compelling open questions in longevity research right now.

References:

Yufan Feng, Marine Barthez, Yifei Wang, Yibing Chen, Huixian Qiu, Chih-Ling Wang, Kartoosh Heydari, Melaine Delcroix, Lene Juel Rasmussen, Vilhelm A. Bohr, Danica Chen. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature, 2026; 657 (8131): 469 DOI: 10.1038/s41586-026-10940-7